Royalty Pharma plc - Class A Ordinary Shares (RPRX)
31.58
-0.01 (-0.03%)
Royalty Pharma Plc is a leading investment firm focused on acquiring and managing pharmaceutical royalties
The company specializes in purchasing royalty streams from innovative drugs and biopharmaceutical products, providing a unique financing solution for biotechnology and pharmaceutical companies. By partnering with these firms, Royalty Pharma helps to fund research and development while benefiting from the commercial success of approved therapies. With a diverse portfolio of royalty agreements across various therapeutic areas, the company plays a pivotal role in the healthcare ecosystem, facilitating access to valuable treatments for patients worldwide.
Cytokinetics receives a Buy rating from Stifel, with a promising outlook for aficamten in the $3 billion U.S. oHCM market, despite investor concerns over M&A and deals.
Jim Cramer likes Walmart (WMT). Walmart provides body cameras to employees in a pilot program. Cramer says Royalty Pharma (RPRX) is a disappointing stock.
Ascendis Pharma reported lower-than-expected Q2 2024 sales of $38.76 million, missing the consensus estimate of $92.7 million due to a significant adjustment to prior sales estimates. The company lowered its full-year sales guidance for Skytrofa. Ascendis also secured a $150 million funding deal with Royalty Pharma based on U.S. sales of Yorvipath.
